Introduction
The most common molecular mechanism of resistance in patients with EGFR activating mutations is the EGFR T790M point mutation in exon 20, which is detected in about half of progressing tumors. 1 However, EGFR T790M mutations are present in 2% of patients with EGFR-mutant lung cancers at time of diagnosis, and they frequently occur concurrently with EGFR TKIsensitizing EGFR mutations. 2 Half of these baseline mutations will be germline mutations, 3 and inheritance is dominant. 4 Unfortunately, the presence of an EGFR T790M mutation at baseline predicts a poor response to treatment with first-and second-generation tyrosine kinase inhibitors (TKIs).
2 Osimertinib (Tagrisso [AstraZeneca Pharmaceuticals, Wilmington, DE]), is a thirdgeneration irreversible EGFR TKI with activity against EGFR TKI-sensitizing mutations and the T790M resistance mutation. [5] [6] [7] It is U.S. Food and Drug Administration-approved for use in patients with metastatic NSCLC with the EGFR T790M mutation who progressed during prior TKI therapy. However, only limited data are available on the efficacy of osimertinib in patients with baseline T790M mutations. Responses were reportedly seen in five treatment-naive patients with T790M mutations in an expansion cohort of the AURA-1 study. 8 However, this was reported in abstract form only. Here we will describe three cases at our institution with baseline EGFR T790M mutations that were treated with osimertinib in the first-line setting for metastatic disease.
Methods
As part of routine clinical care, tumor samples underwent next-generation sequencing in a Clinical Laboratory Improvement Amendments-certified laboratory and were found to have EGFR exon 20 p.T790M mutation. Response to osimertinib treatment was monitored by computed tomography (CT) imaging and clinical examination. When germline mutation evaluation was undertaken, peripheral blood mononuclear cells were sequenced for EGFR mutations.
Results

Patient 1
A 33-year-old white female never-smoker with no family history of lung cancer presented with stage IV (M1b) adenocarcinoma of the lung. CT-guided biopsy of a lung mass revealed adenocarcinoma that was positive for both cytokeratin 7 (CK7) and thyroid transcription factor 1 (TTF-1). Molecular sequencing revealed two mutations in EGFR, an exon 18 p.G719A mutation and an exon 20 mutation p.T790M. Peripheral blood mononuclear cells were sequenced, and the T790M mutation was present, indicating presence of a germline mutation. The G719A mutation was absent from peripheral blood cells. The patient began taking osimertinib, 80 mg daily. By her office visit 3 weeks later, her chest pain had improved. CT scans obtained 7 weeks after the patient had started treatment revealed improvement in her primary lung mass (Fig. 1A) , resolution of the mediastinal lymph nodes, and disappearance of a liver lesion. According to the Response Evaluation Criteria in Solid Tumors 1.1 criteria, she achieved a partial response with a 38% reduction in the sum of target lesions. Her response is ongoing at 5 months.
Patient 2
A 64-year-old white female never-smoker with family history of lung cancer in her mother and maternal grandmother presented with widely metastatic (M1b) adenocarcinoma of the lung. Transbronchial biopsy of the right upper lobe revealed mucin-producing adenocarcinoma that was focally weak positive for TTF-1 and positive for CK7, napsin, and cytokeratin 5/6. Sequencing revealed two EGFR mutations, p.T790M and exon 19 deletion p.L747_T751del. Sequencing of peripheral blood mononuclear cells did not reveal EGFR mutation, which is consistent with somatic mutation. The patient started taking osimertinib, 80 mg once daily, and despite treatment delays and dose reductions, evidence of response (23%) was seen on her first restaging scan, with improvement in the right upper lobe nodule and lymphadenopathy ( Fig. 1A and B) . Her response is ongoing at 8 months.
Patient 3
A 51-year-old white female with a remote 10-packyear smoking history and no family history of lung cancer underwent a CT scan for persistent cough, progressive shortness of breath, and fatigue. The scan revealed a 7.4-cm mass in the right upper lobe adjacent to the superior vena cava as well as bilateral pulmonary nodules that were too numerous to count. Transbronchial biopsy revealed invasive moderately differentiated adenocarcinoma with a micropapillary growth pattern staining positive for TTF-1 and CK7. Sequencing revealed two mutations in EGFR, an exon 18 mutation p.G719A and an exon 20 mutation p.T790M. Sequencing of peripheral blood mononuclear cells to evaluate for germline mutation was not performed. Staging brain magnetic resonance imaging revealed four intracranial metastatic lesions in the bilateral cerebral hemispheres. After completion of stereotactic radiosurgery to the brain metastases, the patient was treated with osimertinib, 80 mg daily. CT scans revealed stable disease by the Response Evaluation Criteria in Solid Tumors 1.1 criteria (a 13% reduction) that continued for 15 months (see Fig. 1A ), until development of central nervous system-only progression.
Conclusions
A small percentage of patients with EGFR mutation will present with either germline or somatic T790M mutations at baseline before receiving any TKI treatment. The published experience is that despite most of these patients also having concurrent EGFR TKI-sensitizing mutations, they do not respond to treatment with first-or second-generation TKIs. To date, the proper management of these patients is undefined. Here we have presented the first published description of patients with metastatic lung adenocarcinoma and either somatic or germline T790M mutation who responded to treatment with osimertinib in the first-line setting. This study suggests that osimertinib treatment should be considered for patients with EGFR T790 mutations in the first-line setting.
